Long-Term Effects of Intermittent IL-2 in HIV Infection: Extended Follow-Up of the INSIGHT STALWART Study
暂无分享,去创建一个
Abdel Babiker | Norman Markowitz | D. Wentworth | N. Markowitz | A. Babiker | J. Tavel | Deborah Wentworth | G. Lopardo | Gustavo Lopardo | Daniela Gey | Lawrence Fox | Jorge Tavel | L. Fox | D. Gey
[1] R. Lempicki,et al. IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. , 2004, Blood.
[2] J. Skinner,et al. Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV , 2011, AIDS.
[3] Douglas A. Hosack,et al. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. , 2005, The Journal of clinical investigation.
[4] R. Davey,et al. A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK–Vanguard Study , 2006, PLoS clinical trials.
[5] R. Davey,et al. The Effect of Intermittent IL-2 Therapy on CD4 T Cells in the Gut in HIV-1–Infected Patients , 2011, Journal of acquired immune deficiency syndromes.
[6] R. Lempicki,et al. Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[7] P. Halfon,et al. Impact of immune interventions on proviral HIV‐1 DNA decay in patients receiving highly active antiretroviral therapy , 2001, HIV medicine.
[8] H. Clifford Lane,et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies , 1997, Nature Medicine.
[9] M. Youle,et al. Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients. , 2008, The Journal of antimicrobial chemotherapy.
[10] J. Metcalf,et al. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. , 2005, The Journal of clinical investigation.
[11] D. Costagliola,et al. IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort. , 2010, The Journal of antimicrobial chemotherapy.
[12] G. Füst,et al. Changes in the levels of some acute‐phase proteins in human immunodeficiency virus‐1 infected patients, following interleukin‐2 treatment , 2010, Clinical and experimental immunology.
[13] R. Davey,et al. Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels , 2009, AIDS.
[14] J. Metcalf,et al. In vivo expansion of CD4+CD45RO–CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patients , 2005 .
[15] C. Hallahan,et al. Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. , 2002, Blood.
[16] J. Tavel. Effects of Intermittent IL-2 Alone or with Peri-Cycle Antiretroviral Therapy in Early HIV Infection: The STALWART Study , 2010, PloS one.
[17] M. Clerici,et al. Qualitative Immune Modulation by Interleukin-2 (IL-2) Adjuvant Therapy in Immunological Non Responder HIV-Infected Patients , 2010, PloS one.
[18] J. Carlis,et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. , 2011, The Journal of clinical investigation.
[19] J. van Lunzen,et al. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial) , 2002, AIDS.
[20] R. Dersimonian,et al. CD4+ T cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation. , 2007, The Journal of infectious diseases.
[21] J. Thèze,et al. Interleukin-7 (IL-7): immune function, involvement in the pathogenesis of HIV infection and therapeutic potential. , 2004, European cytokine network.
[22] H. Lane,et al. Interleukin-2 therapy in patients with HIV infection. , 2009, The New England journal of medicine.
[23] R. Dewar,et al. Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression. , 2000, The Journal of infectious diseases.
[24] Y. Lévy,et al. Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119). , 2009, The Journal of infectious diseases.
[25] R. Lempicki,et al. CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients. , 2008, The Journal of infectious diseases.